Skip to main content

A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat (MK-3543) versus Hydroxyurea in Cytoreductive Therapy Naive Essential Thrombocythemia Participants

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Merck Sharp & Dohme LLC.

Start Date

September 30, 2024

End Date

September 29, 2029
 

Administered By

Duke Cancer Institute

Awarded By

Merck Sharp & Dohme LLC.

Start Date

September 30, 2024

End Date

September 29, 2029